SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-023583
Filing Date
2022-05-03
Accepted
2022-05-03 16:01:55
Documents
59
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0322_lanternphar.htm   iXBRL 10-Q 510382
2 CERTIFICATION f10q0322ex31-1_lanternphar.htm EX-31.1 9975
3 CERTIFICATION f10q0322ex31-2_lanternphar.htm EX-31.2 9918
4 CERTIFICATION f10q0322ex32-1_lanternphar.htm EX-32.1 3595
5 CERTIFICATION f10q0322ex32-2_lanternphar.htm EX-32.2 3512
  Complete submission text file 0001213900-22-023583.txt   3338071

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ltrn-20220331.xsd EX-101.SCH 46697
7 XBRL CALCULATION FILE ltrn-20220331_cal.xml EX-101.CAL 24047
8 XBRL DEFINITION FILE ltrn-20220331_def.xml EX-101.DEF 178378
9 XBRL LABEL FILE ltrn-20220331_lab.xml EX-101.LAB 360415
10 XBRL PRESENTATION FILE ltrn-20220331_pre.xml EX-101.PRE 187953
53 EXTRACTED XBRL INSTANCE DOCUMENT f10q0322_lanternphar_htm.xml XML 314505
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

IRS No.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 22886717
SIC: 2834 Pharmaceutical Preparations